[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pcos-polycystic-ovary-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pcos-polycystic-ovary-syndrome":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,42,66,97,121,148,170,194,218,236,258,286,312,339,365,399,427],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100636917","health-related-quality-of-life-and-metabolic-outcomes-in-pcos-100636917",false,"NCT07571915","Health-Related Quality of Life and Metabolic Outcomes in PCOS","Health-Related Quality of Life and Metabolic Outcomes in PCOS: A Feasibility Study of Comprehensive PCOS Education and Lifestyle Modification Support Delivered Via Synchronous Virtual Groups","Inclusion Criteria:\n\n1. Non-pregnant females ages 18-49 years\n2. Preexisting diagnoses of PCOS and obesity (body-mass index (BMI) equal or greater to 30 kg\u002Fm2) at enrollment\n\nExclusion Criteria:\n\n1. Patients who are pregnant or planning to become pregnant during the study period\n2. Patients currently or with recent participation (\\\u003C 12 months at the time of enrollment) in a PCOS-focused group\n3. Patients with documented monogenic obesity\n4. Patients with a diagnosis of any type of diabetes (with the exclusion of prediabetes)\n5. Patients on systemic glucocorticoid therapy \\> 7 days at the time of enrollment\n6. Patients with any end-stage organ disease\n7. Patients without access to internet\n8. Patients requiring English language interpretation\n9. Any condition which, based on the investigator's medical judgment, would preclude patient ability to complete the study",true,"FEMALE","18 Years","49 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","The primary outcome of interest is change in PCOS health-related quality of life, while the secondary outcome of interest is change in adiposity, cardiometabolic, and inflammation biomarkers.",[28],"PCOS (Polycystic Ovary Syndrome)","RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-01","ACTUAL",{"date":35,"type":33},"2026-06-01",{"date":37,"type":22},"2027-12-31",{"name":39,"class":40},"The Cleveland Clinic","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100638857","mediapp-pcos-a-mobile-mediterranean-diet-app-for-women-with-polycystic-ovary-syndrome-100638857","NCT07598344","MeDiApp-PCOS: A Mobile Mediterranean Diet App for Women With Polycystic Ovary Syndrome","Randomized Controlled Trial of a Mobile Application With Personalized Mediterranean Diet-Based Recommendations in Women With Polycystic Ovary Syndrome","MeDiApp-PCOS","Inclusion Criteria:\n\n* Female participants aged 18 to 45 years.\n* Diagnosis of polycystic ovary syndrome (PCOS) with an anovulatory phenotype according to the Rotterdam criteria (2003).\n* Oligo-ovulation or anovulation, defined as menstrual cycle length greater than 35 days or fewer than 8 menstrual periods per year, together with at least one of the following:\n\n  * Clinical and\u002For biochemical hyperandrogenism.\n  * Polycystic ovarian morphology on ultrasound, defined as at least 20 follicles measuring 2 to 9 mm in either ovary and\u002For ovarian volume of at least 10 cm3.\n* Possession of a smartphone compatible with the study application (Android or iOS).\n* Ability and willingness to use the mobile application and comply with study procedures.\n* Provision of written informed consent before any study-specific procedures are performed.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding at the time of enrollment.\n* Planning pregnancy during the study period.\n* Type 1 or type 2 diabetes mellitus.\n* Other endocrine disorders that may affect reproductive or metabolic function, including Cushing syndrome, congenital adrenal hyperplasia, androgen-secreting tumors, hyperprolactinemia, or uncontrolled thyroid disease.\n* Severe liver disease, including cirrhosis or liver failure.\n* Severe renal impairment, defined as estimated glomerular filtration rate less than 30 mL\u002Fmin\u002F1.73 m2.\n* Severe cardiovascular disease, including unstable angina, myocardial infarction within the previous 6 months, or stroke within the previous 6 months.\n* Use within the previous 3 months of medications that may affect body weight, carbohydrate metabolism, androgen status, or reproductive function, including metformin, oral contraceptives, antiandrogens, gonadotropin-releasing hormone agonists or antagonists, clomiphene citrate, glucocorticoids, thiazolidinediones, or weight-loss drugs.\n* Current or past eating disorders, including anorexia nervosa, bulimia nervosa, or binge eating disorder.\n* Mental disorders or cognitive conditions that, in the opinion of the investigator, would preclude safe participation or compliance with study procedures.\n* Participation in another clinical trial within the previous 3 months.\n* Refusal or inability to provide written informed consent.","45 Years",{"count":52,"type":22},60,[25],"This randomized clinical trial will test whether a mobile application with personalized Mediterranean diet-based recommendations can improve health outcomes in women with polycystic ovary syndrome compared with standard lifestyle advice.\n\nParticipants will be assigned to either the mobile application group or the standard lifestyle advice group.\n\nThe primary outcomes are change in LDL cholesterol and change in body mass index after 3 months.\n\nSecondary outcomes include changes in metabolic and hormonal measures, quality of life, treatment adherence, and ovulatory function assessed through 6 months.",[28],"NOT_YET_RECRUITING","2026-05-31",{"date":59,"type":33},"2026-06-03",{"date":61,"type":22},"2026-05-13",{"date":63,"type":22},"2029-06-30",{"name":65,"class":40},"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100639095","observational-study-on-the-causal-architecture-of-polycystic-ovary-syndrome-pcos-100639095","NCT07623551","Observational Study on the Causal Architecture of Polycystic Ovary Syndrome (PCOS)","An Observational Data Collection Study to Characterize the Hormonal, Metabolic, and Clinical Architecture of Polycystic Ovary Syndrome in Women Aged 18 to 45: A Global Recruitment Initiative","Inclusion Criteria:\n\n* Female\n* Aged 18 to 45 years\n* Diagnosed with Polycystic Ovary Syndrome (PCOS) by a licensed healthcare provider\n* Willing to voluntarily share existing lab results and clinical history\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Over 45 years of age\n* No confirmed PCOS diagnosis from a licensed healthcare provider\n* Unable or unwilling to provide informed consent",{"count":74,"type":22},100,"OBSERVATIONAL","The goal of this observational study is to learn about the causal architecture of Polycystic Ovary Syndrome (PCOS) in women aged 18 to 45. The main questions it aims to answer are:\n\nWhat does the hormonal, metabolic, and clinical architecture of PCOS look like across a diverse global population? Can the causal architecture of PCOS be reconstructed from existing lab results and clinical data? Are there distinct architectural patterns across different groups of women with PCOS? Participants who have been diagnosed with PCOS by a healthcare provider will complete an online questionnaire about their diagnosis, symptoms, clinical history, current treatment, and existing lab results. Participants will also be asked to submit copies of their most recent blood work and lab results. No intervention or treatment is involved. All data is de-identified.",[78,79,80,28],"Polycystic Ovary Syndrome","Polycystic Ovary Syndrome (PCOS)","PCOS",[80,78,82,83,84,85,86,87],"Women's Health","Endocrine","Hormonal","Metabolic","Observational Study","Causal Architecture","2026-05-28",{"date":59,"type":33},{"date":91,"type":22},"2026-06",{"date":93,"type":22},"2026-07",{"name":95,"class":96},"AnnieGuard Corp.","INDUSTRY",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":117,"leadSponsor":119,"locationsCount":41},"100638490","phase-2-efficacy-of-a-glp-1fgf21-dual-agonist-for-treating-pcos-100638490","NCT07616037","Efficacy of a GLP-1\u002FFGF21 Dual Agonist for Treating PCOS","A Preliminary Study to Explore the Efficacy of a GLP-1\u002FFGF21 Dual Agonist (HEC88473) in Patients With Polycystic Ovary Syndrome (PCOS)","Inclusion Criteria:\n\n* Age between 18 and 40 years.\n* Female.\n* No plan for pregnancy from the time of signing the informed consent until 2 months after the last dose of study drug, and willingness to use study-approved contraceptive methods during this period.\n* Fulfillment of at least two of the diagnostic criteria for PCOS according to the 2023 International Guideline, including:\n\n  1. Irregular menstrual cycles:\n\n     1-3 years after menarche: cycle length \\\u003C21 days or \\>45 days; ≥3 years after menarche to perimenopause: cycle length \\\u003C21 days or \\>35 days, or fewer than 8 menstrual cycles per year; ≥1 year after menarche: any cycle \\>90 days;\n  2. Polycystic ovarian morphology: at least one ovary with ≥20 antral follicles (diameter \\\u003C10 mm), confirmed by transvaginal or transrectal pelvic ultrasonography;\n  3. Hyperandrogenism: biochemical hyperandrogenism (total testosterone \\>1.67 nmol\u002FL) or clinical hyperandrogenism (modified Ferriman-Gallwey \\[mFG\\] score \\>4).\n\nExclusion Criteria:\n\n* Use of hormonal contraceptives within 2 months prior to screening.\n* History of acute or chronic pancreatitis or pancreatic injury.\n* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2A or 2B.\n* History of type 1 or type 2 diabetes mellitus.\n* Presence of other endocrine disorders that may cause polycystic ovarian morphology, such as 21-hydroxylase deficiency, pituitary prolactinoma, hypothyroidism, or Cushing's syndrome.\n* Current use of other medications known to affect reproductive function, with discontinuation less than 2 months prior to screening, including GnRH agonists or antagonists, anti-androgens, and gonadotropins.\n* Current use of other medications that may affect metabolism, with discontinuation less than 1 month prior to screening, including metformin, thiazolidinediones, and SGLT2 inhibitors.\n* History of bariatric surgery within the past 12 months.\n* Treatment with GLP-1 receptor agonists within the past 12 months.\n* Pregnancy or lactation.\n* Presence of other serious diseases of major organs such as the heart, liver, or kidney, or any malignancy.\n* Any other condition that, in the investigator's opinion, may interfere with the evaluation of efficacy or safety or render the participant unsuitable for this study.","40 Years",{"count":106,"type":22},30,[108],"PHASE2","Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine and metabolic disorder among women of reproductive age. It is characterized by oligo-ovulation or anovulation, clinical and\u002For biochemical hyperandrogenism, and polycystic ovarian morphology. In addition, PCOS is frequently accompanied by multiple metabolic abnormalities, including insulin resistance, obesity, impaired glucose tolerance, and dyslipidemia. Clinical studies have demonstrated that treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in women with PCOS results in significant weight reduction, decreased free testosterone levels, improvement in menstrual regularity, and increased clinical pregnancy rates. Fibroblast growth factor 21 (FGF21) has been shown to enhance insulin sensitivity, promote fatty acid oxidation, and improve lipid distribution.\n\nHEC88473 is a novel long-acting dual agonist targeting both the glucagon-like peptide-1 (GLP-1) receptor and the fibroblast growth factor 21 (FGF21) receptor. This study is initiated to evaluate the clinical efficacy of HEC88473 in women with PCOS and to explore its potential as a new therapeutic option for the management of PCOS.",[28],[80,112],"GLP-1\u002FFGF21 dual agonist","2026-05-25",{"date":115,"type":33},"2026-05-29",{"date":91,"type":22},{"date":118,"type":22},"2027-12",{"name":120,"class":40},"Shanghai Zhongshan Hospital",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":41},"100610421","symptoms-of-polycystic-ovarian-syndrome-ameliorated-by-keto-adaptation-pilot-100610421","NCT07227363","Symptoms of Polycystic Ovarian Syndrome Ameliorated by Keto-Adaptation Pilot","(SPARK-Pilot)","Inclusion Criteria:\n\n* Female participants aged 18-40 years.\n* Clinical diagnosis of Polycystic Ovary Syndrome (PCOS) according to Rotterdam criteria (presence of at least two of the following: oligo- or anovulation, clinical or biochemical signs of hyperandrogenism, and\u002For polycystic ovaries on ultrasound).\n* Willingness and ability to comply with all study procedures, including fasting (\\>10 hours; water only), avoidance of alcohol (\\>24 hours), and abstaining from exercise (\\>24 hours) prior to each test visit.\n* Willing to maintain current diet, exercise, medication, and supplement habits throughout the study.\n* Body mass index (BMI) ≥18 kg\u002Fm².\n* Access to a smartphone, computer, or tablet for digital tracking and study communication.\n\nExclusion Criteria:\n\n* Current adherence to a low-carbohydrate diet (\\\u003C30% of total energy from carbohydrates).\n* Non-PCOS etiologies of anovulation (e.g., menopause, oophorectomy, or other reproductive disorders).\n* History of type 1 diabetes or uncontrolled type 2 diabetes.\n* Weight loss ≥10% of body weight within the previous 6 months.\n* Pregnancy or breastfeeding.\n* Use of hormonal contraception or medications known to alter reproductive hormones within 3 months prior to enrollment.\n* Active eating disorder or medical condition that could interfere with dietary intervention.\n* Any condition that, in the opinion of the Investigator, could interfere with participation, data integrity, or safety.",{"count":21,"type":22},[25],"The SPARK- Pilot study (Symptoms of PCOS Ameliorated by Responses to Keto-adaptation) is a 12-week clinical trial at The Ohio State University designed to explore how different ways of achieving ketosis may improve reproductive and metabolic health in women with Polycystic Ovary Syndrome (PCOS).\n\nParticipants will be randomly assigned to one of two groups:\n\n* A ketogenic diet group, following a low-carbohydrate, nutrient-dense meal plan.\n* A mixed diet plus ketone supplement group, following general dietary guidelines while taking an exogenous ketone supplement.\n\nThe study will measure whether these approaches help restore regular ovulation and improve hormone balance, metabolism, and overall well-being. Optional imaging using MRI will also examine heart and ovarian health.\n\nThis pilot study will help researchers understand if ketogenic nutrition strategies are a safe, effective way to support menstrual regularity and reduce PCOS-related symptoms, providing groundwork for larger clinical trials.",[28],[133,134,135,136,137,82,138,80],"Ketogenic Diet","Exogenous Ketones","Nutritional Ketosis","Reproductive Hormones","Ovarian Function","Metabolic Health","2026-05-06",{"date":141,"type":33},"2026-05-08",{"date":143,"type":22},"2026-12-01",{"date":145,"type":22},"2026-12",{"name":147,"class":40},"Ohio State University",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":4},"100633998","the-aim-of-this-study-is-to-gain-insight-into-the-occurrence-of-irritable-bowel-symptoms-during-ovarian-stimulation-in-individuals-with-pcos-and-in-women-who-wish-to-freeze-their-eggs-this-study-uses-questionnaires-100633998","NCT07533968","The Aim of This Study is to Gain Insight Into the Occurrence of Irritable Bowel Symptoms During Ovarian Stimulation in Individuals With PCOS and in Women Who Wish to Freeze Their Eggs. This Study Uses Questionnaires.","Fertility Treatment: Impact on Symptoms of Irritable Bowel Syndrome","FIBS","Inclusion Criteria:\n\n* Diagnosis of PCOS according to the 2004 Rotterdam criteria (only for the PCOS group and not for the social freezing group)\n* Initiating their first cycle of IVF treatment (PPOS and freeze only protocol)\n* Nulliparous\n* ≥ 18 years\n* Willing to participate in the study\n* Understanding Dutch, French or English\n\nExclusion Criteria:\n\n* \\- Known inflammatory bowel disorder\n* Known major intestinal bowel disorder\n* Known systemic or auto-immune disorder with implication for the GI system\n* History of abdominal surgery (appendectomy and cholecystectomy allowed if \\>6 months earlier)\n* History of gastro-enteritis in the past 6 weeks",{"count":157,"type":22},120,[25],"This exploratory study investigates the impact of fertility treatments on symptoms of irritable bowel syndrome (IBS) in women. Specifically, the study focuses on two groups:\n\n* Women with polycystic ovary syndrome (PCOS) who are starting their first IVF cycle.\n* Women who choose social freezing (freezing eggs for social reasons).\n\nBackground and Rationale PCOS is an endocrine disorder with hormonal and metabolic abnormalities associated with reduced fertility. There are four PCOS phenotypes, of which phenotypes A and B are the \"classic\" forms. Social freezing is becoming increasingly popular as an option for women without a partner who want to preserve their fertility.\n\nIBS is a common gastrointestinal disorder involving motility disorders and a disturbed gut-brain axis. There is an increased risk of anxiety and depression in IBS patients. Women with PCOS have a twofold increased risk of developing IBS. However, little is known about the effect of hormonal fertility treatments on IBS symptoms.\n\nObjectives\n\n* Primary objective: To investigate whether fertility treatments influence the prevalence and severity of IBS symptoms.\n* Secondary objective: To investigate this change in IBS prevalence and severity in relation to:\n* Changes in anxiety and depression scores.\n* Changes in general gastrointestinal complaints.\n* Subgroup analyses based on:\n* Type of stimulation\n* Duration of desire to have children\n* Ethnicity\n* PCOS type\n* Hormonal and ultrasound response\n\nStudy design The study is a prospective, interventional exploratory study in which participants complete questionnaires before and after the hormonal stimulation phase.\n\n* Start date : March 1, 2026\n* End date of data collection: February 2027\n* Participation locations: Fertility Clinic UZ Brussels\n* Target sample size: 120 women (60 per group)\n\nData collected\n\nBefore treatment:\n\n* Demographics (height, weight, ethnicity)\n* Medical history related to fertility\n* PCOS phenotype (in study arm)\n\nAfter treatment:\n\n* Hormonal values (FSH, LH, estrogen, progesterone)\n* Number of follicles on ultrasound\n* Number of eggs collected\n\nQuestionnaires:\n\n* IBS-SSS (IBS symptom severity)\n* Rome IV and III criteria (IBS diagnosis)\n* GSRS (general GI symptoms)\n* PHQ-9 (depression)\n* GAD-7 (anxiety)\n\nMeasuring instruments\n\n* Rome IV and III criteria: Diagnosis of IBS based on frequency and nature of abdominal pain and changes in bowel movements.\n* IBS-SSS: Five dimensions of IBS symptoms, score between 0 and 500.\n* GSRS: General gastrointestinal complaints in five domains.\n* PHQ-9 and GAD-7: Validation instruments for depression and anxiety.\n\nData management\n\n* Data is collected manually using paper questionnaires.\n* Data is then entered into RedCap.\n* Analysis is performed using SPSS.\n* Strict compliance with GDPR and confidentiality guidelines.\n\nStatistical Analysis\n\n* Logistic regression: To determine the likelihood of meeting the Rome criteria before and after treatment.\n* Multiple linear regression: To identify factors that influence change in IBS-SSS scores.\n* Model selection: Based on AIC (Akaike Information Criterion).\n* Separate analyses for PCOS and social freezing groups.",[28],"2026-04-13",{"date":163,"type":33},"2026-04-16",{"date":165,"type":22},"2026-04-20",{"date":167,"type":22},"2027-05-01",{"name":169,"class":40},"Universitair Ziekenhuis Brussel",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":176,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":184,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":192,"locationsCount":41},"100600846","activegirls-physical-activity-hormone-health-and-diabetes-risk-in-early-adolescence-100600846","NCT07102797","ActiveGirls: Physical Activity, Hormone Health, and Diabetes Risk in Early Adolescence","Inclusion Criteria:\n\n* Caregiver: Caregiver of child (ie mother, father, or other legal guardian), English-speaking, Access to a device where they are able to receive study e-mails or texts\n* Child: English-speaking, Female, ages 8-12 years old at time of enrollment, Pre-menarchal at time of baseline visit, at risk for Polycystic Ovary Syndrome (PCOS)\u002Finsulin resistance, as defined by (1) History of maternal PCOS\u002Fmaternal GDM, (2) BMI \\>\u002F= 85th percentile, (3) History of premature adrenarche, or (4) Small (\\\u003C10th %ile) for gestational age\n\nExclusion Criteria (Child):\n\n* Medications at time of enrollment: Metformin, GLP-1R Agonist, Insulin, GnRH agonist\n* Endocrine conditions that would impact either insulin sensitivity, androgen concentrations, or growth\n* Insulin dynamics: Type 1 diabetes, Type 2 diabetes, Congenital Hyperinsulinism\n* Androgen Conditions: Adrenal tumor, Congenital Adrenal Hyperplasia\n* Hyperthyroidism or uncontrolled hypothyroidism (TSH \\>7.0 mIU\u002FmL)\n* Growth Hormone Deficiency\n* Medical conditions that would impact PA participation: Type 1 diabetes; Cardiovascular, neurologic, and\u002For musculoskeletal conditions limiting ability to participate in physical activity.\n* Other medical comorbidities that would limit generalizability of findings, including: Severe congenital heart disease, Congenital anomalies, Cystic fibrosis, Cerebral palsy, Condition requiring use of nasogastric, gastric tube, or other alternative method of feeding, Undiagnosed conditions with significant impact on child's growth and development; Significant cardiac, hepatic, oncologic, inflammatory, or psychiatric disease.","8 Years",{"count":21,"type":22},[25],"This study explores how a physical activity program can affect hormone health and diabetes risk in girls ages 8-12 who may be at higher risk. The study aims to address:\n\n* Does the 'ActiveGirls' program meet the needs of girls and families in engaging them to increase physical activity?\n* What is the trend of markers of diabetes risk and puberty hormones over a 1-year period and how are these levels related to physical activity levels?\n\nParticipants in this study will either:\n\n* Participate in a 'full' intensity intervention that includes educational messages (text\u002Femail) as well as health coaching visits to support physical activity over a 6 month period\n* Participate in a delayed 'lower intensity' intervention that includes only educational messages (text\u002Femail)\n* Participants in both groups will complete at-home activity monitoring, two study visits for check-ups and tests, and surveys",[28,181,182,183],"Puberty","Insulin Resistance","Physical Activity",[80,185,183],"Prevention","2026-03-17",{"date":188,"type":33},"2026-03-19",{"date":190,"type":33},"2025-11-24",{"date":118,"type":22},{"name":193,"class":40},"Massachusetts General Hospital",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":201,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":216,"locationsCount":41},"100577038","functional-proteins-in-polycystic-ovary-syndrome-100577038","NCT06793098","Functional Proteins in Polycystic Ovary Syndrome","Assessment of the Concentrations of Functional Proteins as Potential Early Markers of Insulin Resistance in Women With Polycystic Ovary Syndrome","Inclusion Criteria:\n\n* women aged 18-45 years\n\nExclusion Criteria:\n\n* removal of at least one ovary\n* treated diabetes of any type\n* diagnosed and treated metabolic diseases\n* diagnosed and treated autoimmune diseases\n* diagnosed and treated autoinflammatory diseases",{"count":74,"type":22},"The concentration of functional proteins: kisspeptin, ghrelin, zonulin will be measured and compared in women with polycystic ovary syndrome (PCOS) and insulin resistance (IR), in women with PCOS without IR, and in women without PCOS.",[204,28],"Reproductive Age",[206,207,208,209,210,78],"insulin resistance","kisspeptin","ghrelin","zonulin","metabolic syndrome",{"date":212,"type":33},"2026-03-18",{"date":214,"type":33},"2025-01-20",{"date":37,"type":22},{"name":217,"class":40},"Jagiellonian University",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":225,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":226,"conditions":227,"keywords":228,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":231,"startDateStruct":232,"completionDateStruct":233,"leadSponsor":235,"locationsCount":41},"100577037","pro--and-anti-inflammatory-cytokines-in-pcos-100577037","NCT06793085","Pro- and Anti-inflammatory Cytokines in PCOS","Assessment of the Concentrations of Pro- and Anti-inflammatory Cytokines and Their Association With the Metabolic Profile of Women With PCOS","Inclusion Criteria:\n\n* women aged 18-45 years\n\nExclusion Criteria:\n\n* previous removal of at least one ovary\n* treated diabetes of any type\n* diagnosed and treated metabolic diseases\n* diagnosed and treated autoimmune diseases\n* diagnosed and treated autoinflammatory diseases",{"count":74,"type":22},"The study will involve measurements and comparisons of the concentrations of pro-inflammatory cytokines: IL-6, TNF-α, IL-18, as well as anti-inflammatory cytokine IL-4 in women with polycystic ovary syndrome (PCOS) and insulin resistance, women with polycystic ovary syndrome without carbohydrate metabolism disorders, and women without PCOS (control group).",[204,28],[229,230,206,210,78],"menstrual disorders","chronic inflammation",{"date":212,"type":33},{"date":214,"type":33},{"date":234,"type":22},"2026-12-31",{"name":217,"class":40},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":242,"maxAge":104,"enrollmentInfo":243,"targetDuration":245,"studyType":75,"phases":4,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":257},"100625708","feasibility-effects-of-a-low-gi-high-fibre-diet-in-pcos-a-prospective-cohort-study-in-remote-yunnan-100625708","NCT07426146","Feasibility Effects of a Low-GI, High-fibre Diet in PCOS: a Prospective Cohort Study in Remote Yunnan","Inclusion Criteria:\n\n* PCOS diagnosis will follow the Rotterdam criteria (presence of two of the following three features: oligo-\u002Fanovulation, clinical\u002Fbiochemical hyperandrogenism, and polycystic ovarian morphology, with exclusion of related disorders). Additional inclusion criteria comprise: body mass index (BMI) ≥24 kg\u002Fm² (Chinese obesity threshold), stable weight for at least 3 months prior to enrollment (±2 kg), willingness to maintain current physical activity levels throughout the study period, and residence within the designated study area for a minimum of 6 months.\n\nExclusion Criteria:\n\n* pregnancy or lactation; type 1 diabetes or type 2 diabetes; thyroid dysfunction, hyperprolactinemia, congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumors, or other endocrine disorders affecting metabolism; use of hormonal contraceptives, insulin sensitizers, or anti-obesity medications within the past 3 months (e.g., metformin, GLP-1 receptor agonists, systemic corticosteroids, hormonal contraceptives, anti-androgens). Severe hepatic\u002Frenal\u002Fcardiovascular disease; gastrointestinal disorders incompatible with high-fiber diets; history of bariatric surgery; current participation in other dietary intervention programs; and individuals with cognitive impairment or language communication barriers who cannot comprehend the study procedures or provide informed consent. Participants will be required to maintain their habitual physical activity levels during the intervention period and must not initiate new weight-loss medications\u002Fsupplements; any deviations will be documented as protocol violations","19 Years",{"count":244,"type":22},56,"6 Months","This study aims to observe the effects of a 6-month, culturally-adapted low glycemic index-high fiber (LGI-HF) dietary on IR, androgen levels, and menstrual regularity among women with PCOS in remote areas of Yunnan Province. We hypothesize that a nutritional strategy designed for high-carbohydrate dietary habits while balancing feasibility and adherence can significantly improve patients' metabolic and reproductive parameters, thereby providing practical evidence-based guidance for long-term PCOS management in resource-limited settings",[28],"2026-02-15",{"date":250,"type":33},"2026-02-23",{"date":252,"type":33},"2025-08-10",{"date":254,"type":22},"2026-04-10",{"name":256,"class":40},"Shanghai First Maternity and Infant Hospital",2,{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":17,"minAge":265,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":23,"phases":268,"briefSummary":269,"conditions":270,"keywords":271,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":41},"100622121","endometrial-response-in-polycystic-ovarian-syndrome-treated-with-letrozole-alone-or-with-added-estradiol-valerate-100622121","NCT07379502","Endometrial Response in Polycystic Ovarian Syndrome Treated With Letrozole Alone or With Added Estradiol Valerate","Endometrial Response in Women With Poorly Primed Endometrial Lining in Diagnosed Polycystic Ovarian Syndrome Treated With Letrozole Alone or With Added Estradiol Valerate","Inclusion Criteria:\n\n* Women aged 20-35 years\n* Clinical diagnosis of PCOS (Rotterdam criteria)\n\nExclusion Criteria:\n\n* Endocrine disorders other than PCOS\n* Endometrial pathology or uterine malformations\n* Allergy to letrozole or estradiol\n* Hormonal therapy within last 3 months","20 Years","35 Years",{"count":52,"type":22},[25],"Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age, characterized by chronic anovulation, hyperandrogenism, and polycystic ovarian morphology. Letrozole, an aromatase inhibitor, has emerged as a first-line ovulation induction agent due to its superior ovulation and pregnancy rates compared to clomiphene citrate. Estradiol valerate, a synthetic estrogen, can be co-administered with letrozole to improve endometrial receptivity by enhancing endometrial thickness, vascularity, and pattern. This study aims to evaluate the effect of letrozole alone versus letrozole with estradiol valerate on endometrial development in these patients.",[28],[28,272,273,274,275],"Letrozole","Estradiol Valerate","Endometrial response","Endometrial thickness","2026-01-27",{"date":278,"type":33},"2026-01-30",{"date":280,"type":22},"2026-03-05",{"date":282,"type":22},"2026-08-31",{"name":284,"class":285},"CMH Kharian Medical College","OTHER_GOV",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":298,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":4},"100619309","the-effects-of-the-mediterranean-diet-and-synbiotics-in-polycystic-ovary-syndrome-100619309","NCT07342946","The Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome","Effects of a Mediterranean Diet and Synbiotic Supplementation on Anthropometric and Biochemical Parameters and Quality of Life in Obese Women With Polycystic Ovary Syndrome","Inclusion Criteria:\n\n* Premenopausal women who are overweight or obese, with a body mass index (BMI) between 25 and 35 kg\u002Fm²\n* Aged 18 to 45 years (reproductive age)\n* Diagnosed with polycystic ovary syndrome (PCOS)\n\nNo underlying metabolic diseases, including type 2 diabetes mellitus, hypertension, diagnosed anemia, or any other metabolic condition requiring a special diet\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding within the past 6 months\n* Presence of comorbid conditions, including kidney, liver, or cardiovascular disease, gout, hyperuricemia, or other related disorders\n* Use of oral contraceptives\n* Following a special dietary treatment or a hypocaloric diet within the last 3 months\n* Occasional or current use of medications that may affect fluid balance, including diuretics and laxatives\n* Participants will be withdrawn from the study in case of abnormal biochemical parameters, non-adherence to the prescribed diet, or failure to comply with the supplementation protoco",{"count":294,"type":22},32,[25],"This study will look at whether a reduced-calorie Mediterranean-style eating plan, together with a synbiotic supplement, can improve health measures and quality of life in women who have polycystic ovary syndrome (PCOS) and are overweight or have obesity. Participants will be assigned by chance (like flipping a coin) to receive either the synbiotic supplement or a placebo (a look-alike product with no active ingredients). All participants will follow the same reduced-calorie Mediterranean diet for 8 weeks. The study team will measure body composition and weight-related measurements, and will collect blood samples to evaluate selected laboratory markers before and after the 8-week period. Participants will also complete the PCOSQ-50 quality-of-life questionnaire before and after the intervention. The goal is to better understand the possible role of synbiotic supplementation alongside dietary treatment in PCOS.",[28],[299,300,301,302],"synbiotics","pcos","diet","nutrition","2026-01-06",{"date":305,"type":33},"2026-01-15",{"date":307,"type":22},"2025-12-20",{"date":309,"type":22},"2027-08-01",{"name":311,"class":40},"Atlas University",{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":17,"minAge":319,"maxAge":242,"enrollmentInfo":320,"targetDuration":4,"studyType":23,"phases":322,"briefSummary":323,"conditions":324,"keywords":327,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":336,"locationsCount":338},"100577582","treatment-of-menstrual-cycle-alterations-in-adolescents-100577582","NCT06800170","Treatment of Menstrual Cycle Alterations in Adolescents","HP-phD_Adolesc","Inclusion Criteria:\n\n* adolescent women aged 14-19 years old, with at least 3 years passed after menarche, and oligomenorrhea or amenorrhea\n\nExclusion Criteria:\n\n* Primary amenorrhea.\n* Hyperandrogenism due to other factors (i.e. adrenal hyperplasia or Cushing syndrome).\n* Hyperprolactinemia or overt hypothyroidism (TSH ≥4).\n* Other hormonal alterations.\n* Ongoing hormonal therapies, including OCPs, six months before enrollment.\n* Ongoing pharmacological therapies.\n* Ongoing use of myo-Inositol supplement or other source of myo-Inositol, or Dioscorea villosa, six months before enrollment.","14 Years",{"count":321,"type":22},20,[25],"the aim of the present study is intended to evaluate how treatment with Myo-Inositol and Dioscorea Villosa can help improve menstrual cycle irregularities in adolescents, both with and without PCOS.",[325,326,28],"Amenorrhea","Oligomenorrhea",[328,329,330],"myo-Inositol","Dioscorea Villosa","adolescents","2026-01-05",{"date":303,"type":33},{"date":334,"type":33},"2025-06-01",{"date":145,"type":22},{"name":337,"class":96},"Lo.Li.Pharma s.r.l",3,{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":266,"enrollmentInfo":347,"targetDuration":4,"studyType":23,"phases":349,"briefSummary":350,"conditions":351,"keywords":352,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":4},"100614023","the-physical-and-mental-impact-of-art-ivm-vs-conventional-ovarian-stimulation-100614023","NCT07274202","The Physical and Mental Impact of ART: IVM vs Conventional Ovarian Stimulation","The Physical and Mental Impact of ART: an RCT Comparing IVM and Conventional Ovarian Stimulation From a Patient Perspective","QolART","Inclusion Criteria:\n\n* Age from \\>18 to \\\u003C35 years\n* Patients with a PCOS diagnosis: The PCOS diagnosis will be based on the ESHRE PCOS guideline (2023) and the evidence-based methodology workshop on polycystic ovary syn-drome, December 3-5, 2012 using the following classification: Phenotype A (hyperandro-genism + oligo-\u002Famenorrhea + PCOM), Phenotype C (hyperandrogenism + PCOM) and Phenotype D (oligo-\u002Famenorrhea + PCOM). Hyperandrogenism is defined as the presence of clinical and\u002For biochemical hyperandrogenism following the ESHRE PCOS guideline, 2023. Oligomenorrhea or amenorrhea is considered as an average cycle duration \\> 35 days.\n* A serum AMH concentration of \\>10.00 ng\u002Fml as measured using the Elecsys platform by Roche at UZ Brussel. Threshold of 10 ng\u002FmL or higher was adopted based on the result of a multivariable analysis by our group (Mostinckx et al. (2024)), which showed that ongoing pregnancy rates in women with AMH of 10ng\u002FmL or higher did not depend on the type of treatment (IVM vs. cOS).\n* Embarking on their first round of ART treatment at Brussels IVF.\n* Eligible for ART either because previous treatment with ovulation induction failed and\u002For because of male factor infertility.\n* Patients must be able to speak Dutch, French or English.\n\nExclusion Criteria:\n\n* BMI \\\u003C18 or \\>35 kg\u002Fm²\n* Patients with a general anesthesia during oocyte retrieval\n* Patients with a PCOS phenotype B will be excluded from the trial since these patients do not polycystic ovaries on ultrasound scan and are therefore not considered hyperrespond-ers.\n* Patients who do not have a partner\n* Need for preimplantation genetic testing (PGT)\n* high grade endometriosis (\\> grade 2)\n* Couples who need donor oocytes",{"count":348,"type":22},84,[25],"Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine conditions, affecting around 10% of women in reproductive age (ESHRE PCOS guideline, 2023).\n\nPCOS is a heterogeneous condition characterized by a combination of Polycystic Ovarian Morphology (PCOM) on ultrasound scan, oligo- or amenorrhea and\u002For hyperandrogenism. Women diagnosed with PCOS are known to have a higher risk for type 2 diabetes mellitus, cardiovascular pathology, pregnancy complications and an impaired quality of life (QoL) (Borghi et al., 2017; ESHRE guideline, 2023). Conventional Ovarian Stimulation (cOS) followed by in vitro fertilization (IVF) or intra cytoplasmic sperm injection (ICSI) is the most frequently used type of ART for PCOS patients. However, women with PCOS often exhibit ovarian hyperresponse to conventional-dose gonadotropin stimulation\u002FcOS, with ovarian hyperstimulation syndrome (OHSS) as the most frequently occurring iatrogenic complication (Vesztergom et al., 2021 ; ESHRE PCOS guideline, 2023). Although, due to a number of strategies to prevent OHSS, the occurrence of severe OHSS has almost been eliminated, with the use of GnRH agonists for final oocyte maturation instead of an hCG trigger as the most efficient strategy, patients might still experience symptoms of abdominal pain and bloating as an indication for mild or moderate OHSS (Bodri et al., 2010 ; Shrem et al., 2019). Aside from the risk for OHSS, patients undergoing cOS, which represents on average a two-week hormonal treatment, may also experience symptoms of hot flushes, breast tenderness, mood swings and higher psychological burden resulting in a reduced QoL during fertility treatment (Barrière et al., 2019; Shrem et al., 2019 ; Adeleye et al., 2020).\n\nIn view of the aforementioned inconveniences of cOS, In Vitro Maturation of oocytes (IVM) followed by ICSI has been proposed as an alternative treatment option in a PCOS population (Trounson et al., 1994 ; ESHRE PCOS guideline, 2023). In Vitro Maturation has been labeled as a more 'patient-friendly' approach, with the ability to further eliminate the risk for OHSS, minimize cycle monitoring (resulting in less in-hospital visits) and reduced side-effects from hormonal ovarian stimulation (Gilchrist and Smitz, 2023; ESHRE PCOS guideline, 2023 ; Vuong et al., 2023). However, to the best of our knowledge, there is only limited research that investigated the prevalence and types of side-effects and the impact on pain scores and QoL of IVM treatment in PCOS patients (Sanmartin et al., under review; Marchante et al., 2024). Therefore, we set out to investigate the impact of IVM on pain scores, side-effects and QoL during fertility treatment in women diagnosed with severe PCOS. We defined severe PCOS as women with a serum AMH\\>10ng\u002FmL because we observed that above this cut-off, cumulative ongoing pregnancy rates were non-inferior after IVM compared to cOS (Mostinckx et al., 2024), with non-inferiority defined as a difference of less than 10% in cumulative ongoing pregnancy rate per cycle.\n\nThis trial is a single center, superiority, randomized controlled trial that will be conducted at Brussels IVF, UZ Brussel, Belgium in a PCOS population, presenting for their first round of ART at Brussels IVF. Each patient can only participate once in this trial.\n\n64 patients are planned to be enrolled in the trial. 32 patients will be required in the control group (cOS group) and 32 patients in the interventional group (IVM group).\n\nPatients will randomly undergo IVM or cOS following randomization. Both treatments will be executed as per treatment as usual (TAU). In both treatment arms, included patients and their partners, will be asked to complete questionnaires at different timepoints after randomization into one of the two treatment arms:\n\n* At the time of counseling (T1)\n* At the end of stimulation (T2)\n* On the day of oocyte retrieval (T3)\n* On the day after oocyte retrieval (T4)\n* At 7 days after oocyte retrieval (T5)\n* At the end of first embryo transfer cycle (T6)\n* End of first ART cycle Used questionnaires are two validated questionnaires, FertiQoL and HADS, and a questionnaire developed to investigate side-effects and pain scores after oocyte retrieval.",[28],[353,354,355,356],"physical side effects","mental side effects","In vitro maturation","conventional ovarian stimulation","2025-11-27",{"date":359,"type":33},"2025-12-10",{"date":361,"type":22},"2026-01",{"date":363,"type":22},"2029-01",{"name":169,"class":40},{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":373,"targetDuration":4,"studyType":23,"phases":374,"briefSummary":375,"conditions":376,"keywords":379,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":41},"100605235","letrozole-extended-vs-traditional-therapy-for-ovulation-induction-in-women-with-pcos-prolex-pcos-100605235","NCT07159880","Letrozole Extended vs Traditional Therapy for Ovulation Induction in Women With PCOS (PROLEx-PCOS)","Extended Therapy Versus Traditional Therapy With Letrozole for Ovulation Induction in Women With Polycystic Ovary Syndrome: A Randomized Controlled Trial","PROLEx-PCOS","Inclusion Criteria:\n\n* Women aged 18 to 40 years;\n* BMI between 18,5 and 31 kg\u002Fm2\n* Diagnosis of Polycystic Ovary Syndrome (PCOS) according to the Rotterdam criteria (2003) (presence of at least two of the following: oligo\u002Fanovulation, clinical and\u002For biochemical hyperandrogenism, polycystic ovarian morphology on ultrasound);\n* Active desire for pregnancy at the time of enrollment;\n* Ability and willingness to provide written informed consent (ICF).\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>40 years;\n* Presence of confirmed bilateral tubal factor, severe male factor infertility, premature ovarian insufficiency, uncontrolled hyperprolactinemia or thyroid dysfunction);\n* Congenital or acquired uterine malformations;\n* History of gynecologic or breast cancer;\n* Known hypersensitivity to, or contraindication for, letrozole;\n* Severe uncontrolled systemic disease (e.g., cardiovascular, renal, or hepatic disorders);\n* Pregnancy or breastfeeding at the time of screening.",{"count":321,"type":22},[25],"This randomized clinical trial aims to compare the efficacy and safety of extended letrozole therapy (5 mg\u002Fday for 10 days) versus standard letrozole therapy (5 mg\u002Fday for 5 days) for ovulation induction in women with polycystic ovary syndrome (PCOS). A total of 84 women aged 18-40 years will be randomized into two groups. Ovulation will be monitored by transvaginal ultrasound and confirmed with urinary LH testing and\u002For corpus luteum presence. The primary outcome is ovulation rate, while secondary outcomes include number and size of mature follicles, clinical pregnancy rate, multiple pregnancy rate, miscarriage rate, number of cycles until pregnancy, and incidence of ovarian hyperstimulation syndrome (OHSS).",[28,377,378],"Infertility","Anovulation",[380,80,381,272,382,383,384,385,386,387,388,389],"polycystic ovary syndrome","Ovulation induction","Aromatase Inhibitor","Extended letrozole therapy","traditional letrozole therapy","standart letrozole therapy","infertility","anovulation","ovulation rate","pregnancy rate","2025-11-23",{"date":392,"type":33},"2025-11-28",{"date":394,"type":33},"2025-09-01",{"date":396,"type":22},"2026-07-30",{"name":398,"class":40},"GABRIEL MONTEIRO PINHEIRO",{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":406,"enrollmentInfo":407,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":409,"conditions":410,"keywords":414,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":41},"100608107","transcriptomic-profiling-of-cumulus-cells-from-capa-ivm-100608107","NCT07197255","Transcriptomic Profiling of Cumulus Cells From CAPA-IVM","Transcriptomic Profiling of Cumulus Cells From CAPA-IVM Cycles in Women With PCOS: A Prospective Pilot Study","Inclusion Criteria:\n\n* Women 18-38 years\n* BMI =\\\u003C 32kg\u002Fm2\n* Diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam 2003 criteria, meet at least 2 of the following 3 features: (1) Oligo-ovulation or anovulation. (2) Clinical and\u002For biochemical signs of hyperandrogenism (3) Polycystic ovarian morphology on ultrasound.\n* Indicated for CAPA-IVM treatment.\n* Serum AMH ≥ 4 ng\u002FmL (28.57 pmol\u002FL).\n* Antral follicle count (AFC) ≥ 24 follicles in both ovaries at the time of CAPA-IVM indication.\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Retrieved sperm from surgical procedures\n* Previous IVF cycle with total immature oocytes","38 Years",{"count":408,"type":22},10,"Capacitation in vitro maturation (CAPA-IVM) has improved oocyte maturation and resulted in live births. Because cumulus cells (CCs) communicate bidirectionally with the oocyte, their transcriptomic profile may serve as a non-invasive biomarker of oocyte and embryo competence. This prospective pilot study will analyze CCs gene expression after CAPA-IVM using RNA sequencing and pathway analysis, and correlate findings with embryological outcomes including fertilization, day-3 cleavage, and blastocyst formation. Results are expected to provide insights into the molecular basis of oocyte competence and support development of non-invasive embryo selection strategies.",[28,411,412,413],"Cumulus Cell","Capacitation IVM","Transcriptomic Profiling",[355,415,416,417],"CAPA-IVM","Cumulus cells","Transcriptomics","2025-11-20",{"date":420,"type":33},"2025-11-21",{"date":422,"type":33},"2025-10-16",{"date":424,"type":22},"2026-03-30",{"name":426,"class":40},"Mỹ Đức Hospital",{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":406,"enrollmentInfo":433,"targetDuration":4,"studyType":23,"phases":435,"briefSummary":436,"conditions":437,"keywords":447,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":41},"100564741","in-vitro-maturation-of-human-eggs-100564741","NCT06633120","In Vitro Maturation of Human Eggs","Inclusion Criteria:\n\n* Infertile women diagnosed with PCOS or polycystic ovaries, or infertile women with good ovarian reserve\n* Antral follicle count (AFC) greater than 24\n* AMH greater than 3.5 ng\u002Fml\n* Body Mass Index less than 35\n* Accept to have embryos biopsied for PGT\n* Intend to perform embryo transfer within 4 months after completing the IVM cycle\n* Paternal (or donor) age \\<45, ejaculated sperm collection only (partner frozen and donor sperm acceptable), sperm morphology (strict criteria) \\>1%, motility \\> 20% and sperm count \\> 10 million per ml (so samples can be prepared through standard procedure)\n\nExclusion Criteria:\n\n* More than 2 failed IVF cycles",{"count":434,"type":22},50,[25],"CCRM Fertility, a global pioneer in fertility treatment, research and science, is seeking participants for a new study on in vitro maturation (IVM). IVM requires less hormones to stimulate the ovaries than IVF, making it more affordable than IVF with fewer side effects. Participants that qualify for the study will receive a free cycle of IVM treatment at CCRM Fertility and including a new patient consultation, fertility testing, preimplantation genetic testing for aneuploidies (PGT-A), anesthesia and some medication",[438,80,28,439,377,440,441,442,443,444,445,446],"Healthy","Ovarian Reserve","Infertility Female","Infertility of Tubal Origin","Infertility Poly Cystic Ovary","AMH","In Vitro Maturation","IVM","IVF",[445,377,80,446],"2024-10-07",{"date":450,"type":33},"2024-10-09",{"date":452,"type":33},"2023-02-03",{"date":454,"type":22},"2030-08-30",{"name":456,"class":40},"Colorado Center for Reproductive Medicine"]